论文部分内容阅读
[目的]探讨同步放化疗及序贯放化疗治疗局部晚期非小细胞肺癌(NSCLC)的疗效及不良反应。[方法]67例局部晚期NSCLC患者分为同步放化疗组(35例)及序贯放化疗组(32例)。同步放化疗组采用紫杉醇40mg/m2,卡铂AUC=2,d1;3DCRT与化疗同时开始,每周1次。序贯放化疗组先行2个周期全身化疗:紫杉醇150mg/m2,卡铂AUC=6,d1,21d为1个周期;第42d开始行3DCRT。[结果]同步放化疗组及序贯放化疗组有效率分别为77%及56%,1年生存率分别为76%和66%,2年生存率分别为39%和32%,差异均无统计学意义(P>0.05)。两组不良反应差异无显著性(P>0.05)。同步放化疗组、序贯放化疗组局部复发率分别为20%(7/35)和31%(10/32),差异有统计学意义(χ2=4.521,P=0.033)。[结论]同步放化疗治疗局部晚期NSCLC疗效较好,但有增加不良反应的可能。
[Objective] To investigate the efficacy and adverse reactions of concurrent chemoradiotherapy and sequential chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer (NSCLC). [Method] 67 patients with locally advanced NSCLC were divided into concurrent chemoradiotherapy group (35 cases) and sequential radiochemotherapy group (32 cases). Paclitaxel 40mg / m2, carboplatin AUC = 2, d1; concurrent with chemotherapy and 3DCRT once a week. Sequential radiotherapy and chemotherapy group first two cycles of systemic chemotherapy: paclitaxel 150mg / m2, carboplatin AUC = 6, d1, 21d for a cycle; 42d began to line 3DCRT. [Results] The effective rates of concurrent chemoradiotherapy and sequential chemoradiotherapy were 77% and 56% respectively, the 1-year survival rates were 76% and 66% respectively, and the 2-year survival rates were 39% and 32% respectively Statistical significance (P> 0.05). Adverse reactions between the two groups showed no significant difference (P> 0.05). The rate of local recurrence in sequential chemoradiotherapy group was 20% (7/35) and 31% (10/32) respectively, with significant difference (χ2 = 4.521, P = 0.033). [Conclusions] Chemotherapy with concurrent chemoradiotherapy is superior to locally advanced NSCLC, but it has the potential of increasing adverse reactions.